P-glycoprotein (MDR1/ABCB1)

Pharmacogenomics of Human Drug Transporters: Clinical Impacts

Volumn , Issue , 2013, Pages 271-293

  Cascorbi, Ingolf ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

ABCB1; Cytostatics; Epilepsy; Immunosuppressants; Leukemia; MDR1; Multi drug resistance; P glycoprotein; P gp; Pharmacogenetics; Pharmacokinetics; Pharmacotherapy resistance; Polymorphism; Protease inhibitors; Transplantation

Indexed keywords

EID: 84886211204     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118353240.ch12     Document Type: Chapter

References (131)

1. Aarnoudse AJ, Dieleman JP, Visser LE, Arp PP, van dH, I, Van Schaik RH, Molokhia M, Hofman A, Uitterlinden AG, Stricker BH (2008) Common ATP-binding cassette B1 variants are associated with increased digoxin serum concentration. Pharmacogenet Genomics, 18, 299-305.
2. Anderson PL, Aquilante CL, Gardner EM, Predhomme J, McDaneld P, Bushman LR, Zheng JH, Ray M, MaWhinney S (2009) Atazanavir pharmacokinetics in genetically determined CYP3A5 expressors versus non-expressors. J Antimicrob Chemother, 64, 1071-1079.
3. Anglicheau D, Le Corre D, Lechaton S, Laurent-Puig P, Kreis H, Beaune P, Legendre C, Thervet E (2005) Consequences of genetic polymorphisms for sirolimus requirements after renal transplant in patients on primary sirolimus therapy. Am J Transplant, 5, 595-603.
4. Baltes S, Fedrowitz M, Tortos CL, Potschka H, Loscher W (2007a) Valproic acid is not a substrate for P-glycoprotein or multidrug resistance proteins 1 and 2 in a number of in vitro and in vivo transport assays. J Pharmacol Exp Ther, 320, 331-343.
5. Baltes S, Gastens AM, Fedrowitz M, Potschka H, Kaever V, Loscher W (2007b) Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam, and carbamazepine by human and mouse P-glycoprotein. Neuropharmacology, 52, 333-346.
6. Basic S, Hajnsek S, Bozina N, Filipcic I, Sporis D, Mislov D, Posavec A (2008) The influence of C3435T polymorphism of ABCB1 gene on penetration of phenobarbital across the blood-brain barrier in patients with generalized epilepsy. Seizure, 17, 524-530.
7. Biedler JL, Riehm H (1970) Cellular resistance to actinomycin D in Chinese hamster cells in vitro: cross-resistance, radioautographic, and cytogenetic studies. Cancer Res, 30, 1174-1184.
8. Bodor M, Kelly EJ, Ho RJ (2005) Characterization of the human MDR1 gene. AAPS J, 7, E1-E5.
9. Bouamar R, HesselinkDA, Van Schaik RH, Weimar W, Macphee IA, de Fijter JW, Gelder TV (2011) Polymorphisms in CYP3A5, CYP3A4, and ABCB1 are not associated with cyclosporine pharmacokinetics nor with cyclosporine clinical end points after renal transplantation. Ther Drug Monit, 33, 178-184.
10. Bournissen FG, Moretti ME, Juurlink DN, Koren G, Walker M, Finkelstein Y (2009) Polymorphism of the MDR1/ABCB1 C3435T drug-transporter and resistance to anticonvulsant drugs: a meta-analysis. Epilepsia, 50, 898-903.
11. Buda G, Maggini V, Galimberti S, Martino A, Giuliani N, Morabito F, Genestreti G, Iacopino P, Rizzoli V, Barale R, et al. (2007) MDR1 polymorphism influences the outcome of multiple myeloma patients. Br J Haematol, 137, 454-456.
12. Campa D, Gioia A, Tomei A, Poli P, Barale R (2008) Association of ABCB1/MDR1 and OPRM1 gene polymorphisms with morphine pain relief. Clin Pharmacol Ther, 83, 559-566.
13. Canaparo R, Finnstrom N, Serpe L, Nordmark A, Muntoni E, Eandi M, Rane A, Zara GP (2007) Expression of CYP3A isoforms and P-glycoprotein in human stomach, jejunum, and ileum. Clin Exp Pharmacol Physiol, 34, 1138-1144.
14. Cascorbi I (2006) Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs. Pharmacol Ther, 112, 457-473.
15. Cascorbi I (2011) P-glycoprotein: tissue distribution, substrates, and functional consequences of genetic variations. In: Handbook of Experimental Pharmacology, Vol. 201. Heidelberg, Germany: Springer. pp 261-283.
16. Cascorbi I, Gerloff T, Johne A, Meisel C, Hoffmeyer S, Schwab M, Schaeffeler E, Eichelbaum M, Brinkmann U, Roots I (2001) Frequency of single-nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther, 69, 169-174.
17. Cascorbi I, Haenisch S (2010) Pharmacogenetics of ATP-binding cassette transporters and clinical implications. Methods Mol Biol, 596, 95-121.
18. Chandler B, Detsika M, Khoo SH, Williams J, Back DJ, Owen A (2007) Factors impacting the expression of membrane-bound proteins in lymphocytes from HIV-positive subjects. J Antimicrob Chemother, 60, 685-689.
19. Chen L, Liu CQ, Hu Y, Xiao ZT, Chen Y, Liao JX (2007) [Association of a polymorphism in MDR1 C3435T with response to antiepileptic drug treatment in ethic Han Chinese children with epilepsy]. Zhongguo Dang. Dai Er. Ke. Za Zhi., 9, 11-14.
20. Chowbay B, Li H, David M, Cheung YB, Lee EJ (2005) Meta-analysis of the influence of MDR1 C3435T polymorphism on digoxin pharmacokinetics and MDR1 gene expression. Br J Clin Pharmacol, 60, 159-171.
21. Colombo S, Soranzo N, Rotger M, Sprenger R, Bleiber G, Furrer H, Buclin T, Goldstein D, Decosterd L, Telenti A (2005) Influence of ABCB1, ABCC1, ABCC2, and ABCG2 haplotypes on the cellular exposure of nelfinavir in vivo. Pharmacogenet Genomics, 15, 599-608.
22. Comets E, Verstuyft C, Lavielle M, Jaillon P, Becquemont L, Mentre F (2007) Modelling the influence of MDR1 polymorphism on digoxin pharmacokinetic parameters. Eur J Clin Pharmacol, 63, 437-449.
23. Coulbault L, Beaussier M, Verstuyft C, Weickmans H, Dubert L, Tregouet D, Descot C, Parc Y, Lienhart A, Jaillon P, Becquemont L (2006) Environmental and genetic factors associated with morphine response in the postoperative period. Clin Pharmacol Ther, 79, 316-324.
24. Crettol S, Deglon JJ, Besson J, Croquette-Krokar M, Hammig R, Gothuey I, Monnat M, Eap CB (2008a) No influence of ABCB1 haplotypes on methadone dosage requirement. Clin Pharmacol Ther, 83, 668-669.
25. Crettol S, Venetz JP, Fontana M, Aubert JD, Ansermot N, Fathi M, Pascual M, Eap CB (2008b) Influence of ABCB1 genetic polymorphisms on cyclosporine intracellular concentration in transplant recipients. Pharmacogenet Genomics, 18, 307-315.
26. Crouthamel MH, Wu D, Yang Z, Ho RJ (2006) A novel MDR1 G1199T variant alters drug resistance and efflux transport activity of P-glycoprotein in recombinant Hek cells. J Pharm Sci, 95, 2767-2777.
27. Curras V, Hocht C, Mangano A, Niselman V, Marino HE, Caceres GP, Mecikovsky D, Bellusci C, Bologna R, Sen L, Rubio MC, Bramuglia GF (2009) Pharmacokinetic study of the variability of indinavir drug levels when boosted with ritonavir in HIV-infected children. Pharmacology, 83, 59-66.
28. del Moral RG, Olmo A, Aguilar M, O'Valle F (1998) P glycoprotein: a new mechanism to control drug-induced nephrotoxicity. Exp Nephrol, 6, 89-97.
29. Dericioglu N, Babaoglu MO, Yasar U, Bal IB, Bozkurt A, Saygi S (2008) Multidrug resistance in patients undergoing resective epilepsy surgery is not associated with C3435T polymorphism in the ABCB1 (MDR1) gene. Epilepsy Res, 80, 42-46.
30. Drescher S, Schaeffeler E, Hitzl M, Hofmann U, Schwab M, Brinkmann U, Eichelbaum M, Fromm MF (2002) MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine. Br J Clin Pharmacol, 53, 526-534.
31. Dulucq S, Bouchet S, Turcq B, Lippert E, Etienne G, Reiffers J, Molimard M, Krajinovic M, Mahon FX (2008) Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood, 112, 2024-2027.
32. Ebid AH, Ahmed MM, Mohammed SA (2007) Therapeutic drug monitoring and clinical outcomes in epileptic Egyptian patients: a gene polymorphism perspective study. Ther Drug Monit, 29, 305-312.
33. Fromm MF (2004) Importance of P-glycoprotein at blood-tissue barriers. Trends Pharmacol Sci, 25, 423-429.
34. Fung KL, GottesmanMM (2009) A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein function. Biochim Biophys Acta, 1794, 860-871.
35. Geick A, Eichelbaum M, BurkO (2001) Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem, 276, 14581-14587.
36. Goralski KB, Hartmann G, Piquette-Miller M, RentonKW (2003) Downregulation of MDR1A expression in the brain and liver during CNS inflammation alters the in vivo disposition of digoxin. Br J Pharmacol, 139, 35-48.
37. Gow JM, Hodges LM, Chinn LW, Kroetz DL (2008) Substrate-dependent effects of human ABCB1 coding polymorphisms. J Pharmacol Exp Ther, 325, 435-442.
38. Haerian BS, Lim KS, Tan CT, Raymond AA, Mohamed Z (2011) Association of ABCB1 gene polymorphisms and their haplotypes with response to antiepileptic drugs: a systematic review and meta-analysis. Pharmacogenomics, 12, 713-725.
39. Hirt D, Mentre F, Tran A, Rey E, Auleley S, Salmon D, Duval X, Treluyer JM (2008) Effect of CYP2C19 polymorphism on nelfinavir toM8biotransformation in HIV patients. Br J Clin Pharmacol, 65, 548-557.
40. Hitzl M, Drescher S, van der KH, Schaffeler E, Fischer J, Schwab M, Eichelbaum M, Fromm MF (2001) The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells. Pharmacogenetics, 11, 293-298.
41. Ho GT, Soranzo N, Nimmo ER, Tenesa A, Goldstein DB, Satsangi J (2006) ABCB1/MDR1 gene determines susceptibility and phenotype in ulcerative colitis: discrimination of critical variants using a gene-wide haplotype tagging approach. Hum Mol Genet, 15, 797-805.
42. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M, Brinkmann U (2000) Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A, 97, 3473-3478.
43. Horinouchi M, Sakaeda T, Nakamura T, Morita Y, Tamura T, Aoyama N, Kasuga M, Okumura K (2002) Significant genetic linkage of MDR1 polymorphisms at positions 3435 and 2677: functional relevance to pharmacokinetics of digoxin. Pharm Res, 19, 1581-1585.
44. Hughes JR (2008) One of the hottest topics in epileptology: ABC proteins. Their inhibition may be the future for patients with intractable seizures. Neurol Res, 30, 920-925.
45. Hung CC, Tai JJ, Lin CJ, Lee MJ, Liou HH (2005) Complex haplotypic effects of the ABCB1 gene on epilepsy treatment response. Pharmacogenomics, 6, 411-417.
46. Hur EH, Lee JH, Lee MJ, Choi SJ, Lee JH, Kang MJ, Seol M, Jang YE, Lee HJ, Kang IS, et al. (2008) C3435T polymorphism of the MDR1 gene is not associated with P-glycoprotein function of leukemic blasts and clinical outcome in patients with acute myeloid leukemia. Leuk Res, 32, 1601-1604.
47. Illmer T, Schuler US, Thiede C, Schwarz UI, Kim RB, Gotthard S, Freund D, Schakel U, Ehninger G, Schaich M (2002) MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients. Cancer Res, 62, 4955-4962.
48. Ishikawa T, Sakurai A, Kanamori Y, Nagakura M, Hirano H, Takarada Y, Yamada K, Fukushima K, Kitajima M (2005) High-speed screening of human ATP-binding cassette transporter function and genetic polymorphisms: new strategies in pharmacogenomics. Methods Enzymol, 400, 485-510.
49. Ishikawa T, Sakurai A, Hirano H, Lezhava A, Sakurai M, HayashizakiY (2010) Emerging newtechnologies in pharmacogenomics: rapid SNP detection, molecular dynamic simulation, andQSARanalysis methods to validate clinically important genetic variants of human ABC transporter ABCB1 (P-gp/MDR1) . Pharmacol Ther, 126, 69-81.
50. Jamroziak K, Mlynarski W, Balcerczak E, Mistygacz M, Trelinska J, Mirowski M, Bodalski J, Robak T (2004) Functional C3435T polymorphism of MDR1 gene: an impact on genetic susceptibility and clinical outcome of childhood acute lymphoblastic leukemia. Eur J Haematol, 72, 314-321.
51. Janneh O, Jones E, Chandler B, Owen A, Khoo SH (2007) Inhibition of P-glycoprotein and multidrug resistance-associated proteins modulates the intracellular concentration of lopinavir in cultured CD4 T cells and primary human lymphocytes. J Antimicrob Chemother, 60, 987-993.
52. Jeong H, Herskowitz I, Kroetz DL, Rine J (2007) Function-altering SNPs in the human multidrug transporter gene ABCB1 identified using a Saccharomyces-based assay. PLoS Genet, 3, e39.
53. Jiang ZP, Wang YR, Xu P, Liu RR, Zhao XL, Chen FP (2008) Meta-analysis of the effect ofMDR1C3435T polymorphism on cyclosporine pharmacokinetics. Basic Clin Pharmacol Toxicol, 103, 433-444.
54. Johne A, Brockmoller J, Bauer S, Maurer A, Langheinrich M, Roots I (1999) Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum) . Clin Pharmacol Ther, 66, 338-345.
55. Johne A, Kopke K, Gerloff T, Mai I, Rietbrock S, Meisel C, Hoffmeyer S, Kerb R, Fromm MF, Brinkmann U, et al. (2002) Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoproteinMDR1 gene. Clin Pharmacol Ther, 72, 584-594.
56. Juranka PF, Zastawny RL, Ling V (1989) P-glycoprotein: multidrug-resistance and a superfamily of membrane-associated transport proteins. FASEB J, 3, 2583-2592.
57. Kafka A, Sauer G, Jaeger C, Grundmann R, Kreienberg R, Zeillinger R, Deissler H (2003) Polymorphism C3435T of the MDR-1 gene predicts response to preoperative chemotherapy in locally advanced breast cancer. Int J Oncol, 22, 1117-1121.
58. Kim DH, Park JY, Sohn SK, Lee NY, Baek JH, Jeon SB, Kim JG, Suh JS, Do YR, Lee KB (2006a) Multidrug resistance-1 gene polymorphisms associated with treatment outcomes in de novo acute myeloid leukemia. Int J Cancer, 118, 2195-2201.
59. Kim DW, Kim M, Lee SK, Kang R, Lee SY (2006b) Lack of association between C3435T nucleotide MDR1 genetic polymorphism and multidrug-resistant epilepsy. Seizure, 15, 344-347.
60. Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV, Schwarz UI, Taylor A, Xie HG, McKinsey J, Zhou S, et al. (2001) Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther, 70, 189-199.
61. Kim YO, Kim MK, Woo YJ, Lee MC, Kim JH, Park KW, Kim EY, Roh YI, Kim CJ (2006c) Single nucleotide polymorphisms in the multidrug resistance 1 gene in Korean epileptics. Seizure, 15, 67-72.
62. Kimchi-Sarfaty C, Gribar JJ, GottesmanMM (2002) Functional characterization of coding polymorphisms in the human MDR1 gene using a vaccinia virus expression system. Mol Pharmacol, 62, 1-6.
63. Kimchi-Sarfaty C, Oh JM, Kim IW, Sauna ZE, Calcagno AM, Ambudkar SV, Gottesman MM (2007) A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science, 315, 525-528.
64. Kishi S, Yang W, Boureau B, Morand S, Das S, Chen P, Cook EH, Rosner GL, Schuetz E, Pui CH, Relling MV (2004) Effects of prednisone and genetic polymorphisms on etoposide disposition in children with acute lymphoblastic leukemia. Blood, 103, 67-72.
65. Kuypers DR, de Jonge H, Naesens M, Vanrenterghem Y (2010) A prospective, open-label, observational clinical cohort study of the association between delayed renal allograft function, tacrolimus exposure, and CYP3A5 genotype in adult recipients. Clin Ther, 32, 2012-2023.
66. Kwan P, Baum L, Wong V, Ng PW, Lui CH, Sin NC, Hui AC, Yu E, Wong LK (2007) Association between ABCB1 C3435T polymorphism and drug-resistant epilepsy in Han Chinese. Epilepsy Behav, 11, 112-117.
67. Lakhan R, Misra UK, Kalita J, Pradhan S, Gogtay NJ, Singh MK, Mittal B (2009) No association of ABCB1 polymorphisms with drug-refractory epilepsy in a North Indian population. Epilepsy Behav, 14, 78-82.
68. Lelong-Rebel IH, Cardarelli CO (2005) Differential phosphorylation patterns of P-glycoprotein reconstituted into a proteoliposome system: insight into additional unconventional phosphorylation sites. Anticancer Res, 25, 3925-3935.
69. Leschziner GD, Andrew T, Leach JP, Chadwick D, Coffey AJ, Balding DJ, Bentley DR, Pirmohamed M, Johnson MR (2007) Common ABCB1 polymorphisms are not associated with multidrug resistance in epilepsy using a gene-wide tagging approach. Pharmacogenet Genomics, 17, 217-220.
70. Levran O, O'Hara K, Peles E, Li D, Barral S, Ray B, Borg L, Ott J, Adelson M, Kreek MJ (2008) ABCB1 (MDR1) genetic variants are associated with methadone doses required for effective treatment of heroin dependence. Hum Mol Genet, 17, 2219-2227.
71. Loscher W, Klotz U, Zimprich F, Schmidt D (2009) The clinical impact of pharmacogenetics on the treatment of epilepsy. Epilepsia, 50, 1-23.
72. Lotsch J, Skarke C, Wieting J, Oertel BG, Schmidt H, Brockmoller J, Geisslinger G (2006) Modulation of the central nervous effects of levomethadone by genetic polymorphisms potentially affecting its metabolism, distribution, and drug action. Clin Pharmacol Ther, 79, 72-89.
73. Lotsch J, Tegeder I, Angst MS, Geisslinger G (2000) Antinociceptive effects of morphine-6-glucuronide in homozygous MDR1a P-glycoprotein knockout and in wild-type mice in the hotplate test. Life Sci, 66, 2393-2403.
74. Lotsch J, von Hentig N, Freynhagen R, Griessinger N, Zimmermann M, Doehring A, Rohrbacher M, Sittl R, Geisslinger G (2009) Cross-sectional analysis of the influence of currently known pharmacogenetic modulators on opioid therapy in outpatient pain centers. Pharmacogenet Genomics, 19, 429-436.
75. Lucia MB, Rutella S, Leone G, Vella S, Cauda R (2001) HIV-protease inhibitors contribute to P-glycoprotein efflux function defect in peripheral blood lymphocytes from HIV-positive patients receiving HAART. J Acquir Immune Defic Syndr, 27, 321-330.
76. Mealey KL, Bentjen SA, Gay JM, Cantor GH (2001) Ivermectin sensitivity in collies is associated with a deletion mutation of the MDR1 gene. Pharmacogenetics, 11, 727-733.
77. Miao LY, Huang CR, Hou JQ, QianMY (2008) Association study of ABCB1 and CYP3A5 gene polymorphisms with sirolimus trough concentration and dose requirements in Chinese renal transplant recipients. Biopharm Drug Dispos, 29, 1-5.
78. Miller DS, Bauer B, Hartz AM (2008) Modulation of P-glycoprotein at the blood-brain barrier: opportunities to improve central nervous system pharmacotherapy. Pharmacol Rev, 60, 196-209.
79. Molinari A, Calcabrini A, Meschini S, Stringaro A, Crateri P, Toccacieli L, Marra M, Colone M, Cianfriglia M, Arancia G (2002) Subcellular detection and localization of the drug transporter P-glycoprotein in cultured tumor cells. Curr Protein Pept Sci, 3, 653-670.
80. Mosyagin I, Runge U, Schroeder HW, Dazert E, Vogelgesang S, Siegmund W, Warzok RW, Cascorbi I (2008) Association of ABCB1 genetic variants 3435C>T and 2677G>T to ABCB1 mRNA and protein expression in brain tissue from refractory epilepsy patients. Epilepsia, 49, 1555-1561.
81. Mourad M, Mourad G, Wallemacq P, Garrigue V, Van Bellingen C, Van Kerckhove V, De Meyer M, Malaise J, Eddour DC, Lison D, et al. (2005) Sirolimus and tacrolimus trough concentrations and dose requirements after kidney transplantation in relation to CYP3A5 and MDR1 polymorphisms and steroids. Transplantation, 80, 977-984.
82. Ozgon GO, Bebek N, Gul G, Cine N (2008) Association of MDR1 (C3435T) polymorphism and resistance to carbamazepine in epileptic patients from Turkey. Eur Neurol, 59, 67-70.
83. Panwala CM, Jones JC, Viney JL (1998) A novel model of inflammatory bowel disease: mice deficient for the multiple drug resistance gene, MDR1A, spontaneously develop colitis. J Immunol, 161, 5733-5744.
84. Petrova DT, Nedeva P, Maslyankov S, Toshev S, Yaramov N, Atanasova S, Toncheva D, Oellerich M, von Ahsen N (2008) No association between MDR1 (ABCB1) 2677G>T and 3435C>T polymorphism and sporadic colorectal cancer among Bulgarian patients. J Cancer Res Clin Oncol, 134, 317-322.
85. Plasschaert SL, Groninger E, Boezen M, Kema I, de Vries EG, Uges D, Veerman AJ, Kamps WA, Vellenga E, de Graaf SS, de Bont ES (2004) Influence of functional polymorphisms of the MDR1 gene on vincristine pharmacokinetics in childhood acute lymphoblastic leukemia. Clin Pharmacol Ther, 76, 220-229.
86. Press RR, Ploeger BA, den Hartigh J, van der ST, van Pelt H, Danhof M, de Fijter H, Guchelaar HJ (2010) Explaining variability in ciclosporin exposure in adult kidney transplant recipients. Eur J Clin Pharmacol, 66, 579-590.
87. Renders L, Frisman M, Ufer M, Mosyagin I, Haenisch S, Ott U, Caliebe A, Dechant M, Braun F, Kunzendorf U, Cascorbi I (2007) CYP3A5 genotype markedly influences the pharmacokinetics of tacrolimus and sirolimus in kidney transplant recipients. Clin Pharmacol Ther, 81, 228-234.
88. Riordan JR, Deuchars K, Kartner N, Alon N, Trent J, Ling V (1985) Amplification of P-glycoprotein genes in multidrug-resistant mammalian cell lines. Nature, 316, 817-819.
89. Rodriguez-Novoa S, Martin-Carbonero L, Barreiro P, Gonzalez-Pardo G, Jimenez-Nacher I, Gonzalez-Lahoz J, Soriano V (2007) Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia. AIDS, 21, 41-46.
90. Ross JR, Riley J, Taegetmeyer AB, Sato H, Gretton S, du Bois RM, Welsh KI (2008) Genetic variation and response to morphine in cancer patients: catechol-O-methyltransferase and multidrug resistance-1 gene polymorphisms are associated with central side effects. Cancer, 112, 1390-1403.
91. Saitoh A, Capparelli E, Aweeka F, Sarles E, Singh KK, Kovacs A, Burchett SK, Wiznia A, Nachman S, Fenton T, Spector SA (2009) CYP2C19 genetic variants affect nelfinavir pharmacokinetics and virologic response in HIV-1-infected children receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr, 54, 285-289.
92. Sakaeda T (2005) MDR1 genotype-related pharmacokinetics: fact or fiction?. Drug Metab Pharmacokinet, 20, 391-414.
93. Sakaeda T, Nakamura T, Horinouchi M, Kakumoto M, Ohmoto N, Sakai T, Morita Y, Tamura T, Aoyama N, Hirai M, et al. (2001a) MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects. Pharm Res, 18, 1400-1404.
94. Sakaeda T, Okamura N, Nagata S, Yagami T, Horinouchi M, Okumura K, Yamashita F, HashidaM (2001b) Molecular and pharmacokinetic properties of 222 commercially available oral drugs in humans. Biol Pharm Bull, 24, 935-940.
95. Schaefer M, Roots I, Gerloff T (2006) In vitro transport characteristics discriminate wild-type ABCB1 (MDR1) from ALA893SER and ALA893THR polymorphisms. Pharmacogenet Genomics, 16, 855-861.
96. Schinkel AH, Mayer U, Wagenaar E, Mol CA, van Deemter L, Smit JJ, van der Valk MA, Voordouw AC, Spits H, van Tellingen O, et al. (1997) Normal viability and altered pharmacokinetics in mice lacking MDR1-type (drug-transporting) P-glycoproteins. Proc Natl Acad Sci U S A, 94, 4028-4033.
97. Schinkel AH, Wagenaar E, Mol CA, van Deemter L (1996) P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest, 97, 2517-2524.
98. Schuetz EG, Furuya KN, Schuetz JD (1995) Interindividual variation in expression of P-glycoprotein in normal human liver and secondary hepatic neoplasms. J Pharmacol Exp Ther, 275, 1011-1018.
99. Seedhouse CH, Grundy M, White P, Li Y, Fisher J, Yakunina D, Moorman AV, Hoy T, Russell N, Burnett A, Pallis M (2007) Sequential influences of leukemia-specific and genetic factors on P-glycoprotein expression in blasts from 817 patients entered into the National Cancer Research Network acute myeloid leukemia 14 and 15 trials. Clin Cancer Res, 13, 7059-7066.
100. Semsei AF, Erdelyi DJ, Ungvari I, Kamory E, Csokay B, Andrikovics H, Tordai A, Csagoly E, Falus A, Kovacs GT, Szalai C (2008) Association of some rare haplotypes and genotype combinations in the MDR1 gene with childhood acute lymphoblastic leukaemia. Leuk Res, 32, 1214-1220.
101. Seo T, Ishitsu T, Ueda N, Nakada N, Yurube K, Ueda K, Nakagawa K (2006) ABCB1 polymorphisms influence the response to antiepileptic drugs in Japanese epilepsy patients. Pharmacogenomics, 7, 551-561.
102. Shahwan A, Murphy K, Doherty C, Cavalleri GL, Muckian C, Dicker P, McCarthy M, Kinirons P, Goldstein D, Delanty N (2007) The controversial association of ABCB1 polymorphisms in refractory epilepsy: an analysis of multiple SNPs in an Irish population. Epilepsy Res, 73, 192-198.
103. Siddiqui A, Kerb R, Weale ME, Brinkmann U, Smith A, Goldstein DB, Wood NW, Sisodiya SM (2003) Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N Engl J Med, 348, 1442-1448.
104. Siegmund W, Ludwig K, Giessmann T, Dazert P, Schroeder E, Sperker B, Warzok R, Kroemer HK, Cascorbi I (2002) The effects of the human MDR1 genotype on the expression of duodenal P-glycoprotein and disposition of the probe drug talinolol. Clin Pharmacol Ther, 72, 572-583.
105. Sills GJ, Mohanraj R, Butler E, McCrindle S, Collier L, Wilson EA, Brodie MJ (2005) Lack of association between the C3435T polymorphism in the human multidrug resistance (MDR1) gene and response to antiepileptic drug treatment. Epilepsia, 46, 643-647.
106. Singh R, Srivastava A, Kapoor R, Mittal RD (2011) Do drug transporter (ABCB1) SNPs influence cyclosporine and tacrolimus dose requirements and renal allograft outcome in the posttransplantation period?. J Clin Pharmacol, 51, 603-615.
107. Skarke C, Jarrar M, Schmidt H, Kauert G, Langer M, Geisslinger G, Lotsch J (2003) Effects of ABCB1 (multidrug resistance transporter) gene mutations on disposition and central nervous effects of loperamide in healthy volunteers. Pharmacogenetics, 13, 651-660.
108. Solas C, Simon N, Drogoul MP, Quaranta S, Frixon-Marin V, Bourgarel-Rey V, Brunet C, Gastaut JA, Durand A, Lacarelle B, Poizot-Martin I (2007) Minimal effect of MDR1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of indinavir in HIV-infected patients. Br J Clin Pharmacol, 64, 353-362.
109. Soranzo N, Cavalleri GL, Weale ME, Wood NW, Depondt C, Marguerie R, Sisodiya SM, Goldstein DB (2004) Identifying candidate causal variants responsible for altered activity of the ABCB1 multidrug resistance gene. Genome Res, 14, 1333-1344.
110. Staatz CE, Goodman LK, Tett SE (2010) Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: part I. Clin Pharmacokinet, 49, 141-175.
111. Stanulla M, Schaffeler E, Arens S, Rathmann A, Schrauder A, Welte K, Eichelbaum M, Zanger UM, Schrappe M, Schwab M (2005) GSTP1 and MDR1 genotypes and central nervous system relapse in childhood acute lymphoblastic leukemia. Int J Hematol, 81, 39-44.
112. Svirnovski AI, Shman TV, Serhiyenka TF, Savitski VP, Smolnikova VV, Fedasenka UU (2009) ABCB1 and ABCG2 proteins, their functional activity and gene expression in concert with drug sensitivity of leukemia cells. Hematology, 14, 204-212.
113. Szoeke C, Sills GJ, Kwan P, Petrovski S, Newton M, Hitiris N, Baum L, Berkovic SF, Brodie MJ, Sheffield LJ, O'Brien TJ (2009) Multidrug-resistant genotype (ABCB1) and seizure recurrence in newly treated epilepsy: data from International Pharmacogenetic Cohorts. Epilepsia, 50, 1689-1696.
114. Taegtmeyer AB, Breen JB, Smith J, Burke M, Leaver N, Pantelidis P, Lyster H, Yacoub MH, Barton PJ, Banner NR (2010) ATP-binding cassette subfamily B member 1 polymorphisms do not determine cyclosporin exposure, acute rejection or nephrotoxicity after heart transplantation. Transplantation, 89, 75-82.
115. Tan NC, Heron SE, Scheffer IE, Pelekanos JT, McMahon JM, Vears DF, Mulley JC, Berkovic SF (2004) Failure to confirm association of a polymorphism in ABCB1 with multidrug-resistant epilepsy. Neurology, 63, 1090-1092.
116. Tanabe M, Ieiri I, Nagata N, Inoue K, Ito S, Kanamori Y, Takahashi M, Kurata Y, Kigawa J, Higuchi S, et al. (2001) Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J Pharmacol Exp Ther, 297, 1137-1143.
117. Terao T, Hisanaga E, Sai Y, Tamai I, Tsuji A (1996) Active secretion of drugs from the small intestinal epithelium in rats by P-glycoprotein functioning as an absorption barrier. J Pharm Pharmacol, 48, 1083-1089.
118. Thorn M, Finnstrom N, Lundgren S, Rane A, Loof L (2005) Cytochromes P450 and MDR1 mRNA expression along the human gastrointestinal tract. Br J Clin Pharmacol, 60, 54-60.
119. Ufer M, Dilger K, Leschhorn L, Daufresne L, Mosyagin I, Rosenstiel P, Haesler R, Kuehbacher T, Nikolaus S, Schreiber S, Cascorbi I (2008) Influence of CYP3A4, CYP3A5, and ABCB1 genotype and expression on budesonide pharmacokinetics: a possible role of intestinal CYP3A4 expression. Clin Pharmacol Ther, 84, 43-46.
120. Ufer M, Mosyagin I, Muhle H, Jacobsen T, Haenisch S, Hasler R, Faltraco F, Remmler C, von Spiczak S, Kroemer HK, et al. (2009) Non-response to antiepileptic pharmacotherapy is associated with the ABCC2-24C>T polymorphism in young and adult patients with epilepsy. Pharmacogenet Genomics, 19, 353-362.
121. Uhr M, Tontsch A, Namendorf C, Ripke S, Lucae S, Ising M, Dose T, Ebinger M, Rosenhagen M, Kohli M, et al. (2008) Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression. Neuron, 57, 203-209.
122. Vahab SA, Sen S, Ravindran N, Mony S, Mathew A, Vijayan N, Nayak G, Bhaskaranand N, Banerjee M, Satyamoorthy K (2009) Analysis of genotype and haplotype effects of ABCB1 (MDR1) polymorphisms in the risk of medically refractory epilepsy in an Indian population. Drug Metab Pharmacokinet, 24, 255-260.
123. van der Holt B, Van den Heuvel-Eibrink MM, Van Schaik RH, van dH, I, Wiemer EA, Vossebeld PJ, Lowenberg B, Sonneveld P (2006) ABCB1 gene polymorphisms are not associated with treatment outcome in elderly acute myeloid leukemia patients. Clin Pharmacol Ther, 80, 427-439.
124. von Richter O, Burk O, Fromm MF, Thon KP, Eichelbaum M, Kivisto KT (2004) Cytochrome P450 3A4 and P-glycoprotein expression in human small intestinal enterocytes and hepatocytes: a comparative analysis in paired tissue specimens. Clin Pharmacol Ther, 75, 172-183.
125. Wang P, Mao Y, Razo J, Zhou X, Wong ST, Patel S, Elliott E, Shea E, Wu AH, Gaber AO (2010) Using genetic and clinical factors to predict tacrolimus dose in renal transplant recipients. Pharmacogenomics, 11, 1389-1402.
126. Winzer R, Langmann P, Zilly M, Tollmann F, Schubert J, Klinker H, Weissbrich B (2003) No influence of the P-glycoprotein genotype (MDR1 C3435T) on plasma levels of lopinavir and efavirenz during antiretroviral treatment. Eur J Med Res, 8, 531-534.
127. Yanagimachi M, Naruto T, Tanoshima R, Kato H, Yokosuka T, Kajiwara R, Fujii H, Tanaka F, Goto H, Yagihashi T, et al. (2010) Influence of CYP3A5 and ABCB1 gene polymorphisms on calcineurin inhibitor-related neurotoxicity after hematopoietic stem cell transplantation. Clin Transplant, 24, 855-861.
128. Yang Z, Wu D, Bui T, Ho RJ (2008) A novel human multidrug resistance gene MDR1 variant G571A (G191R) modulates cancer drug resistance and efflux transport. J Pharmacol Exp Ther, 327, 474-481.
129. Zhang Y, Benet LZ (2001) The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein. Clin Pharmacokinet, 40, 159-168.
130. Zimprich F, Sunder-Plassmann R, Stogmann E, Gleiss A, Dal Bianco A, Zimprich A, Plumer S, Baumgartner C, Mannhalter C (2004) Association of an ABCB1 gene haplotype with pharmacoresistance in temporal lobe epilepsy. Neurology, 63, 1087-1089.
131. Zwisler ST, Enggaard TP, Noehr-Jensen L, Mikkelsen S, Verstuyft C, Becquemont L, Sindrup SH, Brosen K (2010) The antinociceptive effect and adverse drug reactions of oxycodone in human experimental pain in relation to genetic variations in the OPRM1 and ABCB1 genes. Fundam Clin Pharmacol, 24, 517-524.